http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9937756-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_786789bfd666e4d56d14eb2ad998f3ae |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
filingDate | 1999-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0115a5bff3584ea1ac5f470eee9287d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bf9b6e0f4c495a5c9a6be3a9dd8efd4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_542c67d2821a9d3a6102ccf77ae18eb8 |
publicationDate | 1999-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-9937756-A1 |
titleOfInvention | Non-human animal having a functionally disrupted slp-76 gene |
abstract | A non-human animal having somatic and germ cells in which at least one allele of an endogenous SLP-76 gene is functionally disrupted is provided. The animal may be heterozygous or, more preferably, homozygous for the SLP-76 gene disruption and is preferably a mouse. In homozygous animals, the percentage of peripheral T cells is substantially decreased compared to wildtype animals, whereas the percentage of B cells and macrophages in the periphery is substantially normal, indicating that SLP-76 disruption causes a profound block in T cell development. The animals of the invention can be used, for example, as controls to evaluate the efficacy of SLP-76 inhibitors and to identify disease conditions that can be treated with SLP-76 inhibitors. A transgenic non-human animal having a functionally disrupted endogenous SLP-76 gene but which has been reconstituted with an exogenous SLP-76 transgene (e.g., a human SLP-76 gene or a SLP-76 gene whose expression in targeted to a particular cell population) is also provided. An animal that has been reconstituted with a human SLP-76 gene can be used to identify agents that modulate human SLP-76 in vivo. Nucleic acid constructs for functionally disrupting an endogenous SLP-76 gene in a host cell, recombinant vectors including the nucleic acid construct, and host cells into which the nucleic acid construct has been introduced are also encompassed by the invention. |
priorityDate | 1998-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 446.